Resverlogix Corp logo

Resverlogix Corp

NEW
STU:RFS (Canada)  
€ 0.051 (0%) Jun 26
At Loss
Market Cap:
€ 17.68M ($ 20.47M)
Enterprise V:
€ 36.83M ($ 42.63M)
Volume:
0
Avg Vol (2M):
0
Trade In:

Business Description

Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Name Current Vs Industry Vs History
Equity-to-Asset
-11.3
Debt-to-Equity
-0.24
Debt-to-EBITDA
-22.44
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
44.54
9-Day RSI
45.87
14-Day RSI
46.62
3-1 Month Momentum %
-23.88
6-1 Month Momentum %
-9.73
12-1 Month Momentum %
155

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.03
Quick Ratio
0.02

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-2.7
Shareholder Yield %
-33.17
Name Current Vs Industry Vs History
ROA %
-78.46
ROIC %
-20.63
3-Year ROIIC %
49.88
ROC (Joel Greenblatt) %
-16434.78
Years of Profitability over Past 10-Year
1
Moat Score
4
Tariff Resilience Score
6
Name Current Vs Industry Vs History
EV-to-EBIT
-31.44
EV-to-EBITDA
-44.58
EV-to-FCF
-9.86
Earnings Yield (Greenblatt) %
-3.18
FCF Yield %
-21.13

GF Valueâ„¢

Resverlogix Corp Filings

Filing Date Document Date Form
No Filing Data

Resverlogix Corp Stock Events

Financials Calendars
Event Date Price (€)
Third quarter earnings results for 2026 2026-11-13 In 138 days
Second quarter earnings results for 2026 2026-08-14 In 47 days
General meeting for 2026 2026-06-25 15:00 0.05 (+3.06%)
First quarter earnings results for 2026 2026-05-15 0.06 (+11.32%)
Annual report for 2025 2026-04-10 0.06 (+5.26%)
Fourth quarter earnings results for 2025 2026-04-10 0.06 (+5.26%)
Third quarter earnings results for 2025 2025-11-13 0.06 (-9.02%)
Second quarter earnings results for 2025 2025-08-14 0.07 (-12.16%)
General meeting for 2025 2025-06-30 13:00 0.02 (-18.37%)
First quarter earnings results for 2025 2025-05-14 0.02 (-15.79%)
Show
Entries

Articles on Resverlogix Corp

No articles.